AMB Consulting is a consulting firm providing guidance and direction to entrepreneurs as their businesses are transitioned, typically around significant transactions.

YPrime is a specialty technology and services provider dedicated to helping biopharmaceutical sponsors achieve greater certainty and accurate outcomes in their clinical trials by seamlessly leveraging technology and operational excellence. YPrime innovates by providing leading-edge eClinical technology and data consulting services and has more than a decade of focused experience with eClinical systems to expedite and improve the quality of patient management and clinical data. Cloud-based electronic clinical outcome assessment (eCOA) and interactive response technology (IRT) platforms offer sponsors greater speed, precision and integration in clinical trial management.

Cotinga Pharmaceuticals,TSX Venture Exchange listed company, is a clinical-stage pharmaceutical company that uses proprietary artificial intelligence technologies to pursue a targeted and transformational approach to treating cancer and other unmet medical needs. The Company’s lead compound, COTI‐2, has a novel p53‐dependent mechanism of action with selective and potent anti‐cancer activity. P53 mutations occur in over 50% of all cancers. COTI‐2 is initially being evaluated in combination with various standard of care chemotherapy regimens for the treatment of a wide spectrum of cancers in a Phase 1b/2a clinical trial at the MD Anderson Cancer Center at the University of Texas and the Lurie Cancer Center at Northwestern University. The Company has secured orphan drug status in the United States for COTI‐2 for the treatment of ovarian cancer. Preclinical data suggests that COTI-2 could dramatically improve the treatment of cancers with mutations in the p53 gene.The Company’s second lead compound, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS function. KRAS mutations occur in up to 30% of all cancers and represent a tremendous unmet clinical need and a desirable drug target. COTI-219 is undergoing IND-enabling studies to support a regulatory submission.

Miratech is a global IT services and consulting company that supports digital transformation for the largest enterprises in the world and brings together global enterprise innovation and start-up innovation.

Bracket (now Signant Health) is a specialty services provider dedicated to helping biopharmaceutical sponsors achieve greater certainty and accurate outcomes in their clinical trials by seamlessly leveraging science, technology, and operational excellence. Bracket innovates at the leading-edge of clinical research data, one exceptional service at a time. From the advanced technology of our eCOA electronic Clinical Outcomes Assessments flexible platform, to the efficiency of our scalable and configurable Randomization and Trial Supply Management (RTSM) Clinical IRT solution, to our science-focused Rater Training and Quality Assurance programs, Bracket does it faster, better and with an eye on the future of our industry.

Sanguine is bridging the gap between patients and researchers in the clinical R&D process by developing a novel @home clinical trial platform that increases efficiency, transparency and big data collection. Our mission is to develop technologies that empower patients to participate in advancing research for their condition. Through this approach, we widen patient reach for more efficient recruitment, decrease patient burden for improved retention, and lower site work effort for reduced costs.

Strategic advisor to the founderNSC is a professional staffing contractor with nearly $100 million in revenues that specializes in staffing and workforce management solutions for a wide range of industries.

Aptiv Solutions (Now Icon PLC) is a contract research, decision support/technology organization focused on the outsourced bio-pharmaceutical drug development sector. Grew the business from zero to combined revenue nearly $175M with market-leading technology products and 850 professionals (23 offices across 14 countries). Matt delivered strategic capital raising, strategic planning, forecasting, corporate development, accounting and control, tax, risk management, investor relations, budgeting, and finance initiatives.► Strategy focused on decision support technologies, consulting services, and business processes. Developed a business plan and secured more than $100M in equity commitments from three private equity firms.► Acquired 8 companies in the US, Europe and Japan during the first 3+ years and integrated these multinational companies onto a single, operational platform.► Created the recognized market leader in adaptive clinical trials for drug and devices which resulted in the successful sale of the company to Icon, PLC, a strategic buyer and a complete monetization at closing for all stakeholders.

PRA International, Inc (now PRA Health Sciences) provides a broad spectrum of solutions from full-service clinical development to embedded solution models.From investor relations, corporate development, forecasting, SEC compliance, treasury, accounting and control, tax, risk management, procurement, and real estate initiatives, Matt provided the financial leadership, client relations, and strategies that produced revenue growth on a compounded annual rate of 25% over five years and operating income expansion of 49%. ► Oversaw successful IPO and secondary offerings, raising $275+M ► Acquired and fully integrated seven strategic companies financed with internally generated capital, PRA stock and commercial bank commitments.► Managed the global treasury function, designing and implementing a global, multi-currency enterprise-wide project finance system that was adopted by the entire organization.► Successfully designed and implemented a complex Sarbanes-Oxley program for a multinational organization.

Marriott International's Senior Living Services division owned and operated senior independent full-service and assisted living communities with a revenue of $1.2+B.Brought on board to provide strong financial leadership, Matt put into place several innovative strategies and solutions that improved overall operations and financial controls. Identifying opportunities to improve processes, he undertook several projects (including re-engineering the Medicare billing function) that significantly improved cash flow.► Established the division level owner relations’ function that understood and managed owner expectations, designed protocols to respond to owners’ requests, and defining roles and responsibilities for operating and financial personnel.► Executed the sale of $2B in senior living communities in six separate transactions.

A senior member of Business Advisory group, which led Andersen's consulting work related to business strategy, business process development, and transaction support. Led client engagements in the mid-Atlantic region.